POOLBEG PHARMA ORD 0.02P news, videos and press releases
For more news please use our advanced search feature.
POOLBEG PHARMA ORD 0.02P - More news...
POOLBEG PHARMA ORD 0.02P - More news...
- HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
- HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
- Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
- Poolbeg Pharma PLC Announces Notification of Major Holdings
- Poolbeg Pharma PLC Announces Change of Registered Address
- Poolbeg Pharma PLC Announces Result of AGM
- Poolbeg Pharma PLC Announces Annual Report & AGM Notice
- Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
- Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
- Poolbeg Pharma PLC Announces Appointment of Joint Broker
- Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
- Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
- Poolbeg Pharma PLC Announces POLB 001 US Patent Update
- Poolbeg Pharma PLC Announces Director/PDMR Shareholding
- Poolbeg Pharma PLC Announces Director Share Purchase
- Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
- Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
- Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
- Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
- Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
- Poolbeg Pharma PLC Announces Directorate Change
- Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
- Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
- Former Amryt Pharma Leadership Team join Poolbeg
- Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
- Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
- Poolbeg Partners with a Nasdaq-Listed Biopharma
- Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
- Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
- Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
